82 results
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
of their fiduciary duties. They may also reduce the likelihood of derivative litigation against the registrant’s directors and executive officers
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
“prohibited activities” (as defined in Section 10A of the Exchange Act).
3.12 Litigation. Except as set forth in the SEC Reports, there is not pending
8-K
EX-1.1
ofesqs
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.2
j4fze2 h6up74wc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
t70r9pga
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
q4sv15
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-10.1
166sr4
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-1.1
baa ptmfiy8
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
dvg2pvl8e1dhxy 2e
30 Mar 22
Prospectus supplement for primary offering
5:21pm